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We have previously shown that urokinase plasminogen
activator (uPA) stimulates the growth of human ker-
atinocytes in culture. For this effect, uPA activity
is essential to generate the active amino terminal
fragment, by an autolytic process. Our findings indi-
cated further that inhibition of uPA may result in
the suppression of growth of keratinoytes. Here, we
provide evidence that plasminogen activator inhibitor
(PAI)-2 has an anti-proliferative effect on ker-
atinocytes. The uPA activity in cultured keratinocytes
increased in parallel with cell proliferation, reaching a
maximum level at confluency and decreasing gradually
thereafter. The analysis of synchronized cells showed
that the peak uPA activity in the medium occured just
prior to S-phase, suggesting that the production and
Plasminogen activator inhibitor (PAI)-2 was first disco-vered in human placenta as a specific inhibitor ofurokinase plasminogen activator (uPA) (Kawano et al,1968; Holmberg et al, 1978). Although PAI-2 can alsoinhibit tissue plasminogen activator (tPA), inhibition of
tPA is less effective in comparison with that of uPA (Kruithof et al,
1995). PAI-2 is widely distributed in various cells and tissue fluids
such as macrophages, fibroblasts, vascular cells, pregnancy plasma,
and gingival cervicular fluid (Kruithof et al, 1995). In addition,
PAI-2 is the predominant epidermal PA inhibitor throughout the
normal epidermis (Hibino et al, 1986). An endothelial type PA
inhibitor, PAI-1, is also known in mammals (van Mourik et al,
1984). PAI-1, which can inhibit both uPA and tPA to a similar
extent, is structurally and functionally distinct from PAI-2
(Pannekoek et al, 1986). Both PAI belong to the serine proteinase
inhibitor (serpin) family (Potempa et al, 1994); however, PAI-2 is
categorized in a subfamily called ‘‘ov-serpin’’, which shows an
evolutionarily separated branch from other serpins (Remold-
O’Donnel, 1993). In addition to PAI-2, the ov-serpin subfamily
also includes ovalbumin, SCC antigen, and neutrophil elastase
inhibitor and others (Remold-O’Donnel, 1993; Kruithof et al,
1995).
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secretion of uPA is related to cell proliferation. In
contrast, PAI-2 levels showed a steady increase, even
after confluency. When PAI-2, purified from human
cornified cells, was added to synchronized ker-
atinocytes, S-phase was no longer evident and the
peak uPA activity was eliminated. In experiments
with a bacterially expressed PAI-2 fusion protein,
[3H]thymidine incorporation by keratinocytes was sig-
nificantly suppressed, confirming an anti-proliferative
effect of PAI-2. These results strongly suggest that
PAI-2 is involved in the regulation of keratinocyte
proliferation and differentiation. Key words: cell syn-
chrony/growth inhibition/serpin/uPA. J Invest Dermatol
112:85–90, 1999
It has been well documented that PA are involved in various
physiologic reactions in vivo. The fibrin binding property of tPA
suggests that tPA takes part mainly in fibrinolysis in plasma (Danø
et al, 1985). On the other hand, biologic functions of uPA seem
more complex. uPA binds to a specific uPA receptor (Blasi et al,
1986) and localizes its activity on the cell surface. uPA-mediated
biologic functions such as tissue remodeling, cell migration, and
cancer cell metastasis (Ellis et al, 1992) seem to depend on the
membrane-bound form. Targeting the uPA and tPA genes by the
homologous recombination technique, Carmeliet et al (1994)
further extended the observation about the physiologic functions
of PA. Mice with inactivation of the uPA gene suffered occasional
fibrin deposition. tPA-deficient mice demonstrated impaired clot
lysis. Mice with combined deficiency resulted in retarded growth,
reduced fertility and life expectancy, as well as extensive fibrin
deposition. These results reveal that uPA and tPA have distinct
roles in various physiologic conditions.
There is growing evidence that uPA may be mitogenic to certain
cells. Kirchheimer et al (1989) reported that active uPA is essential
for the growth stimulation of the human epidermal cell line, CCL
20.2. Rabbani et al (1990) isolated a mitogenic factor from the
culture medium of osteoblast-like cells and identified it as the
amino terminal fragment of uPA. The amino terminal fragment is
liberated from the proteinase domain by autolysis at position Arg135
(Stoppelli et al, 1985). In normal epidermis, both PA activity and
mRNA are not detectable (Baird et al, 1990); however, in pathologic
conditions such as psoriasis where abnormal proliferation of ker-
atinocytes is evident, PA activity is one of the characteristic features
of the disease (Grønhahl-Hansen et al, 1987, 1988). In contrast,
the upper epidermis contains predominantly PAI-2 (Hibino et al,
1988). The localization of PAI-2 in the epidermis seems to correlate
with terminal differentiation of the keratinocytes.
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In this study we focused on the uPA–PAI-2 relationship in
keratinocyte proliferation. Our findings demonstrate that produc-
tion and secretion of uPA correlate with the cell cycle and thus
proliferation of the keratinocytes. PAI-2, purified from human
cornified cells, had a growth inhibitory effect on cultured ker-
atinocytes. This anti-proliferative activity was also demonstrated
using recombinant PAI-2. Therefore, our results, obtained under
two different conditions, strongly suggest that PAI-2 is involved in
the regulation of keratinocyte proliferation.
MATERIALS AND METHODS
Materials TintElize uPA and TintElize PAI-2 were purchased from
Biopool (Edinburgh, U.K.). PyroGlu-Gly-Arg-p-nitroanilide (pNA)
(S-2444) and Val-Leu-Lys-pNA (S-2251) were the products of Kabi
Diagnostica (Stockholm, Sweden). uPA was purchased from Green Cross
(Osaka, Japan). Plasminogen-free fibrinogen was obtained from Daiichi
Pure Chemicals (Tokyo, Japan). Thymidine, hydroxyurea, and trichlo-
roacetic acid were purchased from Wako Pure Chemical Industries (Tokyo,
Japan). [Methyl-3H]thymidine (85 Ci per mmol) was purchased from
Amersham Japan (Tokyo, Japan).
Cell culture and proliferation assay Normal human epidermal ker-
atinocytes (second passage) were obtained from Krabo (Osaka, Japan) and
cultured with serum-free KGM medium (Clonetics, San Diego, CA).
Keratinocytes were used before the third passage in all experiments
described. After trypsin treatment, keratinocytes were plated at 5 3 103
cells per well and cultured for 48 h at 37°C under 5% CO2. Ten microliters
of 1 mCi of [3H]thymidine was added for 24 h. Excess [3H]thymidine was
washed away with phosphate-buffered saline (PBS) and the cells were
treated with 0.25% trypsin 1 0.02% ethylene diamine tetraacetic acid and
transferred to glass microfiber filters (GF/C, Whatman). Radioactivity in
trichloroacetic acid-insoluble materials was measured using an LS6000 beta
counter (Beckman, Fullerton, CA).
Cell synchronization Exponentially growing keratinocytes were syn-
chronized into S phase by treatment with thymidine and hydroxyurea
(Goyns, 1980; Cidlowski and Cidlowski, 1982) based on a doubling time
determined in preliminary experiments to be 40 h. Briefly, keratinocytes
were cultured in 12 well plates until they reached µ60% confluency.
Thymidine was added to the culture medium to give a final concentration
of 2.5 mM and incubated for 26 h. After washing twice with PBS, the
cells were incubated in fresh KGM medium for 14 h. Synchrony was
accomplished by the addition of hydroxyurea to a final concentration of
1 mM and by incubating the cells for an additional 24 h. To assess cell
synchrony, [3H]thymidine (0.5 mCi per ml) was incorporated for 90 min.
Cells were harvested by trypsin treatment and radioactivity was measured
as described above.
Amount of uPA and PAI-2 Amount of uPA was estimated using
TintElize uPA according to the manufacturer’s instructions. For this purpose
keratinocytes were cultured with 6 well plates and 1 d old conditioned
medium was used for the detection of soluble uPA. In order to estimate
cell-associated uPA, keratinocytes at the different confluent stages (50%,
80%, 100%, and 2 d after confluency) were collected with a cell scraper
and extracted with 0.5 ml of 0.1 M Tris-HCl (pH 8.0) 1 0.5% Triton
X-100 including protease inhibitor cocktail, ‘‘Complete’’ (Boehringer,
Mannheim, Germany). Homogenization was performed using a glass
homogenizer and cell extracts were treated four times with repeated
freezing and thawing. After centrifugation, supernatant was used as the
cellular phase, which includes membrane-bound and intracellular uPA.
Distribution of soluble and cellular PAI-2 was also measured using TintElize
PAI-2. In this case, 2 ml of conditioned medium was dialyzed and
lyophilized to concentrate PAI-2. Lyophilized samples were dissolved in
200 µl of PBS and used for the detection of soluble PAI-2. Cell-associated
PAI-2 was estimated using the same extracts described above.
Plasminogen activator and plasminogen activator inhibitor
assays PA activity in the culture medium was measured using the
plasminogen-supplemented two-step assay. Briefly, every 2 d 10–50 µl of
conditioned medium were removed from the culture and mixed with
reaction buffer [0.1 M Tris-HCl (pH 8.8) 1 0.1% Tween 80] to a final
volume of 100 µl to which 50 µl of 0.2 mg purified dog plasminogen per
ml were added. This mixture was incubated at 37°C for 30 min. After
mixing with 50 µl of 0.2 M phosphate buffer (pH 7.0) containing 0.2 M
NaCl, 50 µl of 1 mM synthetic substrate for plasmin (S-2251) were added
and incubated for appropriate times. The reaction was stopped by the
addition of 50 µl of 30% acetic acid. Changes in absorbance were read at
405 nm using an EIA reader (BioRad, Hercules, CA).
For the purification of PAI-2 or recombinant PAI (rPAI)-2, inhibitor
activity for urokinase was monitored with a direct inhibition method. Ten
microliters of sample, 10 µl of urokinase (240 IU per ml), and 70 µl of
the reaction buffer were mixed and preincubated for 30 min. The reaction
was started by the addition of 10 µl of 2 mM S-2444 and incubated for
30 min. Samples for the enzyme-linked immunosorbent assays were
prepared by lyophilizing 1 ml of culture medium from two wells at every
2 d. Lyophilized materials were redissolved in 50 µl of the sample buffer
supplied by the manufacturer and 10 µl were used for each assay.
Concentration of uPA was calculated from the purified uPA sample as
standard. uPA was purified using benzamidine-Sepharose affinity chromato-
graphy (Holmberg et al, 1976). The concentration of active uPA was
calculated based on the specific activity of 96,000 IU per mg protein.
Characterization of PAI-2 by western blot Keratinocytes were plated
at 2500 cells per cm2 and cultured in 24 well plates. Every 2 d, 0.5 ml of
culture medium from three different plates was collected and lyophilized
after dialysis. Lyophilized materials were reconstituted in 20 µl of sample
buffer for sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(Laemmli, 1970). After electrophoresis, separated protein bands were
blotted onto a PVDF membrane (BioRad), immersed twice in 2.5% Triton
X-100 for 30 min each to remove SDS, and washed with PBS. The
membrane was then reacted with goat anti-PAI-2 antibody (CosmoBio,
Tokyo, Japan) and visualized with an HRP-conjugated anti-goat secondary
antibody using DAB as a substrate.
Fibrin autography Every 2 d, 1 ml of conditioned medium from two
wells was lyophilized and reconstituted in 50 µl of the SDS sample buffer.
After duplicate electrophoreses, fibrin autography was carried out following
the method of Granelli-Piperno and Reich (1978). Briefly, the gels were
washed in 2.5% Triton X-100 to remove SDS. The gels were then layered
on indicator gel slabs containing 1.2% agarose, thrombin (0.06 unit per
ml), and fibrinogen (2 mg per ml), with or without purified plasminogen
(5 µg per ml). Fibrin gels were stained with Amido Black 10B. The ratio
between enzyme-inhibitor complex and free-u-PA was calculated by
weighing the lysis areas that were cut from the photograph of the gel.
Purification of PAI-2 from cornified cell extract PAI-2 was purified
according to the method of Hibino et al (1986) with modifications. Briefly,
human cornified cells scraped from heels of healthy individuals were
extracted with Tris-buffered saline. After concentration using an Amicon
YM-10 membrane, the extract was applied to a DEAE-Sepharose column
equilibrated with 20 mM Tris-HCl (pH 8.0). The inhibitor fraction was
collected and applied to a Sephacryl S-200 column. PAI-2 was purified by
successive FPLC Mono Q chromatographies at pH 8.0 and 7.0.
Construction of rPAI-2 Human keratinocytes were cultured in KGM
medium in a 175 cm2 flask to 80% confluency. After washing the cultures
three times with PBS, SDS denaturing solution was directly applied to the
flask and mRNA was isolated using a Fast Track mRNA isolation kit
(Invitrogen, San Diego, CA). PAI-2 cDNA was cloned by a combination
of reverse transcription and polymerase chain reaction techniques based on
the sequence reported by Ye et al (1987). Primers used were 5’CGGAATT-
CATGGAGGATCTTTGTGTGGCA39 for the upper primer that includes
an Eco RI site and 59GCTTCGAATTAGGGTGAGCAAAATCTGCC39
for the lower primer that contains a Hind III site. A polymerase chain
reaction product was digested with Eco RI and Hind III, gel-purified, and
then ligated into the pMAL-2c vector (New England Biolabs, Beverly,
MA). This cDNA clone was sequenced and confirmed that the clone had
no mutation. First we made recombinant PAI-2 with GST fusion protein
system. This did not show any inhibitor activity against uPA even at the
100 times excess concentration. So, we employed the maltose binding
protein (MBP) fusion system. The expression vector was introduced into
E. coli JM109. Bacteria were cultured in 1 liter of LB and the expression
of the fusion protein was induced by 0.2 mM isopropyl-1-thio-b-D-
galactopyranoside. After centrifugation, the cells were destroyed by
sonication. rPAI-2 fusion protein was purified using maltose-affinity chro-
matography.
RESULTS
uPA and PAI-2 show distinct changes in keratinocyte culture
medium The overall uPA activity in the culture medium depends
on the activation of pro-uPA (single chain uPA) and the inhibition
of activated uPA by PAI-2. We analyzed changes of the total
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Figure 1. uPA and PAI-2 show distinct changes in keratinocyte
culture medium. The amounts of total uPA (d) and PAI-2 (j) in the
medium were measured by enzyme-linked immunosorbent assay. The
amount of active uPA (s) was calculated from a specific activity of 96,000
IU per mg protein after measuring the uPA activity with plasminogen-
supplemented two-step assay. After trypsinization, keratinocytes were
collected and cell number (n) was counted using a hemocytometer. Each
symbol represents the mean and SD of six experiments. Keratinocytes
reached confluency around day 8. Spontaneous shedding began around
day 13.
amount of uPA, active uPA, and PAI-2, as well as cell number
during the culture. The amount of total uPA and the uPA activity
in the medium peaked on the sixth day, just before the cultures
reached confluency on the eighth day (Fig 1). Approximately
140 ng uPA per ml were detected on the sixth day and elevated
levels were maintained up to the tenth day. On day 12, the quantity
of uPA decreased abruptly to 50 ng per ml and increased again on
day 14 when spontaneous shedding was observed. Levels of active
uPA correlated with the amount of total uPA up to the twelfth
day. During this period, µ60% of the uPA secreted was converted
to active uPA as calculated from the specific activity of 96,000 IU
per mg protein. Changes of PAI-2 were different from those of
uPA and showed a continuous increase throughout the culture
except on the sixteenth day, when the cell number was considerably
decreased as a result of shedding. Levels of PAI-2 never exceeded
those of uPA. PAI-2 in the culture medium remained low until
keratinocytes became confluent; however, the relatively large
amounts were present in the medium after day 14. Considering
the number of the keratinocytes in the culture, which peaked
around day 12 prior to spontaneous shedding on day 14, it was
obvious that keratinocytes in the growing phase secreted more uPA
into medium. In addition, levels of PAI-2 during the growing
phase were kept considerably low compared with the latter stage
of the culture.
Distribution of uPA and PAI-2 between soluble and cellular
phases Because uPA is known to bind to the specific uPA
receptor on the surface of keratinocytes, production of uPA or
PAI-2 is the sum of soluble, membrane-bound, and intracellular
fractions. We have analyzed soluble and cellular (membrane-bound
and intracellular) phases. Figure 2 summarizes the distribution of
uPA and PAI-2 at the different confluent stages, respectively. More
than 85% of uPA synthesized by keratinocytes was always secreted
into culture medium. The ratio between soluble and cellular uPA
remained constant until keratinocytes reached the confluency.
Soluble uPA showed a moderate increase to 93% after the conflu-
ency. On the other hand, PAI-2 showed considerable difference.
Up to the confluency, only 5% of PAI-2 was found in the soluble
fraction, although it showed some increase to 10% 2 d after
confluency.
Figure 2. Distribution of uPA and PAI-2 between soluble and
cellular phases. Ratio between soluble and cellular phases was expressed
as percentile. Total amounts of uPA and PAI-2 at 50%, 80%, 100%, and 2 d
after confluency (120%) were estimated by enzyme-linked immunosorbent
assays, respectively. Each ratio was calculated from the mean of three
different experiments. Dotted area shows soluble fraction and shaded area
indicates cellular fraction.
Figure 3. PAI-2 is present as complexes throughout the culture.
Every 2 d, 0.5 ml of conditioned medium was collected and lyophilized.
Presence of PAI-2 was analyzed by western blot using goat anti-PAI-2
antibody. Purified PAI-2 from human cornified cells (43 kDa,
nonglycosylated form) was used as a control (left lane). High molecular
weight bands seen throughout the culture correspond to the uPA–PAI-2
complex. After day 14, uncomplexed glycosylated (60 kDa) and
nonglycosylated (43 kDa) species of PAI-2 are observed.
PAI-2 is present as complexes during growing
phase Western blot analysis of the culture medium demonstrated
a band of approximately Mr 90,000 throughout the culture (Fig 3).
Such a band corresponds to the complex between uPA and PAI-2
(Wun and Reich, 1987). The mechanism of uPA inhibition by
PAI-2 includes cleavage by uPA at Arg381 in the susceptible loop
and complex formation with the newly formed carboxy end
(Stoppelli et al, 1985). The complex was SDS resistant and recogniz-
able by the anti-PAI-2 antibody. uPA-PAI-2 complex was detectable
from day 2 to day 16. At day 14, an additional band with Mr
60,000 was observed. This band would be the glycosylated form
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Figure 4. uPA is present in free and complexed forms in culture
medium. Every 2 d, conditioned medium was collected and SDS–
polyacrylamide gel electrophoresis samples were prepared after dialysis and
lyophilization. Condition of uPA in culture medium was analyzed by fibrin
autography. Translucent bands demonstrate the fibrin-degraded area caused
by uPA in the medium. Intact uPA activity was seen up to day 12 with a
maximum lysis area observed at day 8. uPA activity derived from the uPA-
PAI-2 complex was also visualized as a high molecular weight band by
this method. From day 10, an additional band appeared above this lysis
area that represents the complex with the glycosylated form of PAI-2.
of PAI-2 (Genton et al, 1987). At day 16, in addition to the band
with Mr 60,000, there was also a band with Mr 43,000 that is
identical to intact PAI-2. These two species demonstrate that free
forms of PAI-2 were present only in the later stages of the culture
period, where no more proliferation was observed.
uPA is present in a free and complexed form in culture
medium When plasminogen-containing gels were used to detect
uPA activity, control uPA showed a translucent band with Mr
54,000. Free uPA in the conditioned medium increased until day
8, when keratinocytes reached confluency, and gradually decreased
thereafter. With this method, it is also possible to detect the uPA–
PAI-2 complex (Wun and Reich, 1987). After gel electro-
phoresis, uPA activity will be recovered from the enzyme-inhibitor
complex at the position where the complex migrated (Fig 4).
uPA–PAI-2 complex was observed from day 4 to day 16. Double
bands of the complex from day 10 imply glycosylated and nonglyco-
sylated forms of PAI-2 (Genton et al, 1987). Note that free form
of uPA was detected until the twelfth day when cell number
reached its highest. Plasminogen-free fibrin gel did not show any
lysis area (data not shown), demonstrating the specificity of this
method for the detection of PA activity.
PAI-2 suppresses keratinocyte proliferation Cell synchrony
was monitored at 2.5 h intervals by measuring [3H]thymidine in
trichloroacetic acid-insoluble material from keratinocyte extracts
(Fig 5a). The majority of the keratinocytes were synchronized by
the treatment used. A peak of [3H]thymidine uptake, indicating
the S phase, was seen between 17.5 h and 20 h. The addition of
10 µg purified PAI-2 per ml suppressed thymidine uptake to the
basal level and a distinct S-phase could no longer be identified.
We also tried 1 µg per ml concentration of the purified PAI-2
(data not shown). [3H]Thymidine incorporation was somewhat
lower; however, S-phase was still recognizable in the presence of
1 µg PAI-2 per ml. We measured the PA activity in the medium
and found that relatively high PA activity was still detectable.
uPA was not evenly present during the cell cycle. The S-phase
correlated with PA activity. Peak PA activity in control cultures
was found to be at 17.5 h, just prior to the S phase (Fig 5b). This
activity was abolished by the PAI-2 treatment. These results imply
that the production and secretion of uPA is a specific event
associated with the keratinocyte cell cycle. In the presence of
purified PAI-2, uPA activity in the medium and the cell cycle were
effectively inhibited.
Characterization of purified rPAI-2 fusion protein Purified
rPAI-2 fusion protein showed a single protein band with an Mr
95,000 (data not shown). This fraction demonstrated inhibitor
activity against uPA (Fig 6). Specific activity of the fusion protein
Figure 5. Effect of PAI-2 on cell cycle. (a) PAI-2 suppresses
[3H]thymidine incorporation. Cell synchrony was attained with thymidine
and hydroxyurea treatment as described in Materials and Methods. Peak
thymidine uptake indicating the S-phase is seen between 17.5 and 20.0 h
of the cell cycle (d). The inhibition of S-phase by purified PAI-2 is
indicated from the suppression of thymidine incorporation at all time
points in the cultures supplemented with PAI-2 (s). Final concentration
of the purified PAI-2 added in the medium was 10 µg per ml. Each symbol
represents the mean and SD of three experiments. (b) Changes of PA
activity in cell cycle. PA activity in the conditioned medium in synchronous
culture was measured every 2.5 h (d). Note the peak PA activity at 17.5 h
in the new cell cycle. In a separate experiment, the culture medium was
replaced every 2.5 h with fresh medium containing 10 µg purified PAI-2
per ml (s). Under these conditions, uPA activity was effectively suppressed
and remained at basal level. Each symbol represents the mean and SD of
four experiments.
was calculated to be 10,000 inhibitor units per mg protein. This
value is 10% of intact PAI-2, which shows 100,000 inhibitor units
per mg protein (Stoppelli et al, 1985). Because the MBP-fusion
protein has an Mr 95,000, specific activity of the fusion protein
should be considered to be twice the calculated value. This value,
however, is still only one-fifth of the theoretical specific activity.
This difference is probably due to the bacterial expression system,
because it is known that bacterially expressed proteins do not fold
properly and as a result sometimes lack functional activities.
Attempts to cleave the fusion protein with Factor Xa under different
conditions destroyed most of the rPAI-2 activity. We therefore
used recombinant PAI-2 as a fusion protein.
Anti-proliferative effect of recombinant PAI-2 fusion protein
on keratinocyte growth The addition of rPAI-2 fusion protein
dramatically suppressed [3H]thymidine uptake at the concentration
of 1 µM (95 µg per ml) (Fig 7a). That this inhibitory effect does
not result from the MBP portion of the fusion protein is indicated
from the observation that MBP did not show any effect on
[3H]thymidine uptake at any concentrations tested (Fig 7b). The
observation that concentrations of the fusion protein below 1 µM
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Figure 6. Inhibition of uPA by PAI-2 fusion protein. PAI-2 cDNA
was polymerase chain reaction cloned and expressed as a fusion protein
using a pMAL-c2 vector. PAI-2 fusion protein was purified using an
amylose affinity column. The fusion protein inhibited uPA activity in a
dose dependent manner. Concentration of uPA used was 1 µg per ml.
Each symbol represents the mean and SD of three experiments.
did not show any suppression, indicates that a threshold level of
PAI-2 is required to overcome the uPA activity in the condi-
tioned medium.
DISCUSSION
A growth stimulatory effect of uPA has frequently been cited in
cancer cell proliferation; however, the mechanisms of this effect
have remained obscure. Our recent observation that uPA can
also stimulate keratinocyte proliferation in culture1 indicates an
involvement of uPA in the growth stimulation of nonmalignant
cells as well. This proliferative effect on keratinocytes is uPA specific
and does not involve the classical PA system. Indeed, plasmin is
not required for this reaction, showing a characteristic feature of
this process. In this study we further analyzed the relationship
between uPA and its regulator, PAI-2, produced by the cultured
human keratinocytes.
In the epidermis of normal individuals, PAI-2 is localized in the
differentiated keratinocytes of the spinous layer and above (Hibino
et al, 1988). In cultures of keratinocytes, we observed a steady
increase of PAI-2 in the conditioned medium even after the cells
reached confluency. This pattern is distinctly different from that of
uPA, which showed a marked decrease when keratinocytes reached
confluency. Analysis of distribution between soluble and cellular
fractions demonstrated that the majority of uPA were secreted into
the culture medium, whereas most of PAI-2 was found to remain
in the cellular fraction. These findings clearly showed the dominance
of uPA in the culture medium during the proliferative condition.
uPA was found as a pro-form, an active form, and a complex form.
Although uPA–PAI-2 complex was detected throughout the culture
period, free and active uPA was highest during the growing phase.
Western blot analysis demonstrated that most of PAI-2 was present
as complexes until cell number reached its maximum at day 12,
and then free PAI-2 appeared in the culture medium. Both
glycosylated and nonglycosylated forms of PAI-2 were seen under
these culture conditions. Fibrin autography clearly showed that the
intact uPA activity was observed up to the twelfth day of the
culture, whereas it was no longer seen in the later stages. Together
these results show that high level of uPA activity is accompanied
with the keratinocyte proliferation in an early stage of the culture
and it is suppressed where no more growth is observed after the
confluency.
The analysis of the synchronized keratinocytes demonstrated that
1Hibino T, Lenthaldt D, Takahashi T, Baciu PC, Goetinck PF: Mechan-
ism of keratinocyte growth stimulation by urokinase plasminogen activator
(uPA). J Invest Dermatol 104:645, 1995 (abstr.)
Figure 7. Effect of recombinant PAI-2 on keratinocyte growth. (a)
Anti-proliferative effect of recombinant PAI-2 fusion protein on
keratinocyte growth. PAI-2 fusion protein at 1 µM had a statistically
significant inhibition on 3thymidine incorporation (*p , 0.05,
**p , 0.001). Each symbol represents the mean and SD of six experiments.
(b) Lack of effect of MBP on keratinocyte growth. MBP did not show
any effect on [3H]thymidine incorporation at the concentrations tested.
Each symbol represents the mean and SD of six experiments.
uPA activity in the culture medium was highest just prior to the
S-phase. In contrast, an increased appearance of uPA and tPA
shortly after the S-phase was reported during a synchronous cycle
of a rat adenocarcinoma cell line, PA-III (Scott et al, 1987). Thus
it is clear that the appearance of uPA is regulated during the cell
cycle even though the results of the two studies indicate that
regulatory mechanisms for PA production and/or secretion may
differ depending on cell types.
The relationship between cell proliferation and uPA is probably
the reason why uPA is barely detectable in the basal layer of normal
epidermis, where only a small number of dividing cells are observed.
On the other hand, both uPA and tPA mRNA were demonstrated
by in situ hybridization in psoriatic lesional skin (Spiers et al,
1994). Although tPA predominated and localized in the superficial
keratinizing cells of the psoriatic epidermis, staining for uPA was
found to be focal in and between the basal keratinocytes, in which
the proliferative population resides (Grønhahl-Hansen et al, 1987).
Co-localization of tPA and its substrate plasminogen in lesional
psoriatic skin may suggest the role of tPA in efficient generation
of plasmin (Gissler et al, 1993). Not only psoriasis but other
epidermal hyperproliferation were accompanied by elevated levels
of uPA mRNA and activity (Jensen and Lavker, 1996). They also
showed that uPA, but not PAI-1 or PAI-2, was consistently elevated
in the proliferative population of keratinocytes. uPA production
seems to be promoted by these proliferating keratinocytes in
disease conditions. In cultures of keratinocytes the cell cycle was
considerably suppressed and S-phase was no longer evident in the
presence of 10 µg PAI-2 per ml, which were sufficient to inhibit
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all the uPA activity in the medium. Physiologic concentration of
PAI-2 varies depending on tissues and tissue fluids. In gingival
fluid, for example, it reaches 2–8 µg per ml (Kinnby et al, 1993),
showing that the concentration of PAI-2 used in this study is
comparable and remains in a physiologic range. Even so, it was
demonstrated that 10 µg PAI-2 per ml, which is 100 times more
than that needed to inhibit uPA in the medium, was necessary to
accomplish total suppression of uPA activity as well as [3H]thymidine
incorporation. Because cellular uPA fraction shared only a small
portion compared with soluble uPA, we still do not know why
excess PAI-2 was necessary for the suppression of this reaction. It
is unlikely that the membrane-bound uPA can consume large
amounts of exogenous PAI-2, although PAI-2 is capable of inhibit-
ing cell-associated uPA (Kruithof et al, 1995). The fact that the
inhibition of soluble uPA was attained only by the high concentra-
tion of PAI-2 showed that it was certainly necessary at least in the
culture condition. One possible explanation is that PAI-2 may not
be stable in the culture medium and continuously synthesized uPA
may soon overcome exogenous and endogenous PAI-2.
Together the results presented in this study revealed the involve-
ment of uPA in keratinocyte proliferation and the anti-proliferative
activity of PAI-2. Accordingly, the uPA–PAI-2 relationship would
be important in various physiologic and pathologic conditions. It
has often been stated that levels of uPA or uPA receptor are
associated with cancer cell invasion (Duffy et al, 1990; Ossowski
et al, 1991; Grønhahl-Hansen et al, 1993). In breast cancer, the
level of expression of uPA receptor seems to be correlated with poor
prognosis (Bianchi et al, 1994). On the other hand, overexpression of
PAI-2 was shown to suppress cancer cell metastasis (Laug et al,
1993; Mueeler et al, 1995). These phenomena were interpreted to
be solely dependent on the ability to degrade surrounding matrix
proteins with proteinases that were activated by the PA-plasmin
system and the effect of PAI-2 was interpreted as the inhibition of
the activation process. Our observation revealed that PAI-2 has an
anti-proliferative effect in addition to an anti-metastatic effect, and
thus this function should also be considered in the process of cancer
cell metastasis. According to this view the inhibition of uPA would
be beneficial not only in preventing the metastatic cascade, but
also in suppressing cancer cell proliferation.
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